Biotech Co.* | Pharma Co. | Product | Terms/Details (Date) |
| | |||
AEterna Laboratories | Mayne Group | Neovastat | Mayne Group will market Neovastat in Australia, New Zealand, Canada and Mexico (10/2) |
Avax Technologies | Grupo Ferrer | AC vaccine technology | Agreement for sales and distribution of AC vaccine technology in Europe, Latin America and certain Asian territories; AVAX will retain all manufacturing rights and will sell the vaccine to Grupo Ferrer; AVAX will receive manufacturing payments, as well as milestone payments upon marketing and registration goals (10/1) |
Endovasc Ltd. Inc. | Cardinal Health | Angiogenix | Cardinal Health will formulate Angiogenix according to cGMP FDA standards (10/21) |
Enzon Inc. (ENZN) | Elan Corp. plc | Abelcet | Enzon gained a sales force of about 60 in the agreement to acquire North American and Japanese marketing rights to Abelcet; the agreement is worth $370M (10/2) |
Genelabs Technologies | Patheon Inc. | Prestara | Commercial supply agreement for the systemic lupus erythematosus candidate; Patheon will manufacture and supply Prestara capsules for distribution in North America and Europe (9/19) |
ILEX Oncology Inc. | BTG International | Campath | ILEX acquired global exclusive commercial rights to Campath-related diagnostics, including CD52 antigen testing; financial terms were not disclosed (10/8) |
Keryx Biopharmaceuticals | Opocrin SpA | KRX-101 | Keryx gained worldwide manufacturing rights to KRX-101 (10/3) |
KS Biomedex | Medison Pharma | TransMID | Medison will distribute TransMID in Israel; Medison will make an undisclosed equity investment in KSB and contribute clinical support to the pivotal Phase III trial (10/9**) |
ML Laboratories | Undisclosed | Two drugs in the breath-actuated dry powder inhaler, Clickhaler | The agreement includes access fees and milestone payments of £10 (US$15.7), and double-digit royalties (9/18**) |
Nabi | IDIS World | Nabi-HB | IDIS will provide named-patient distribution coverage in 43 countries (10/22) |
NPS Pharmaceuticals | Boehringer | Preos | Boehringer will manufacture commercial quantities of bulk drug supplies of Preos (10/21) |
Paladin Labs Inc. | Novo Nordisk | GlucaGen | Paladin Labs obtained Canadian distribution rights to GlucaGen (9/23) |
ProdiGene Inc.* | Sigma-Aldrich | TrypZean | Sigma-Aldrich will manufacture and distribute TrypZean; financial terms were not disclosed (10/10) |
Viragen Inc. | CJ Pharma | Multiferon | CJ Pharma will distribute Viragen's human alpha interferon in designated Latin American countries; agreement is for five years (10/23) |
| | |||
Notes: | |||
# The information in the chart does not cover agricultural agreements or those between biotech companies. | |||
* Private companies are indicated with an asterisk. | |||
** Denotes the date the item ran in BioWorld International. | |||
Unless otherwise noted, stock symbols listed are on the Nasdaq market. | |||
AMEX = American Stock Exchange; OTC BB = Over-the-Counter Bulletin Board; TSE = Toronto Stock Exchange | |||
